Actively Recruiting
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-05-11
60
Participants Needed
5
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
CONDITIONS
Official Title
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult 18 years or older
- Diagnosis of S. aureus bacteremia within the past 48 hours with either unknown MRSA status in areas with less than 15% MRSA prevalence or known negative MRSA screening within 90 days, or confirmed MSSA infection
- Currently receiving cefazolin or considered appropriate to switch to cefazolin as backbone therapy
- Up to 12-24 hours of open-label vancomycin, linezolid, or daptomycin allowed if MRSA has not been excluded and sepsis is present
You will not qualify if you...
- Clinical improvement with at least one subsequent negative culture after more than 24 hours incubation at recruitment
- History of anaphylaxis to any beta-lactam antibiotic or allergy to ertapenem
- Polymicrobial bacteremia (excluding skin commensals)
- Known seizure disorder
- Current use of valproic acid
- Expected mortality within 48 hours
- Need for critical care but do not resuscitate status prevents critical care
- Unable to provide informed consent and no healthcare proxy available (unless ethics-approved deferred consent)
- Refusal to provide informed consent
- Refusal of healthcare team participation
- No reliable outpatient contact method
- Previous enrollment in the study
- Identification of MRSA isolate after enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Foothills Medical Centre
Calgary, Alberta, Canada, T2N4Z6
Actively Recruiting
2
Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital)
Hamilton, Ontario, Canada, L8P1A2
Actively Recruiting
3
Niagara Health - St. Catharines site
Saint Catharines, Ontario, Canada, L2E6X2
Actively Recruiting
4
Hospital de la Cité de la Sante
Laval, Quebec, Canada
Actively Recruiting
5
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
Montreal, Quebec, Canada, H4A3J1
Actively Recruiting
Research Team
L
Lina Petrella
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here